JP2022536345A5 - - Google Patents
Info
- Publication number
- JP2022536345A5 JP2022536345A5 JP2021573421A JP2021573421A JP2022536345A5 JP 2022536345 A5 JP2022536345 A5 JP 2022536345A5 JP 2021573421 A JP2021573421 A JP 2021573421A JP 2021573421 A JP2021573421 A JP 2021573421A JP 2022536345 A5 JP2022536345 A5 JP 2022536345A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- fusion protein
- variant polypeptide
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024216112A JP2025063029A (ja) | 2019-06-14 | 2024-12-11 | がんの治療ための新規インターロイキン－２バリアント |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962861651P | 2019-06-14 | 2019-06-14 | |
| US62/861,651 | 2019-06-14 | ||
| US201962947806P | 2019-12-13 | 2019-12-13 | |
| US62/947,806 | 2019-12-13 | ||
| PCT/US2020/037644 WO2020252418A2 (en) | 2019-06-14 | 2020-06-13 | Novel interleukin-2 variants for the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024216112A Division JP2025063029A (ja) | 2019-06-14 | 2024-12-11 | がんの治療ための新規インターロイキン－２バリアント |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022536345A JP2022536345A (ja) | 2022-08-15 |
| JP2022536345A5 true JP2022536345A5 (https=) | 2023-08-07 |
| JP7607938B2 JP7607938B2 (ja) | 2025-01-06 |
Family
ID=73782252
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021573421A Active JP7607938B2 (ja) | 2019-06-14 | 2020-06-13 | がんの治療ための新規インターロイキン－２バリアント |
| JP2024216112A Pending JP2025063029A (ja) | 2019-06-14 | 2024-12-11 | がんの治療ための新規インターロイキン－２バリアント |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024216112A Pending JP2025063029A (ja) | 2019-06-14 | 2024-12-11 | がんの治療ための新規インターロイキン－２バリアント |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220235109A1 (https=) |
| EP (1) | EP3983433A4 (https=) |
| JP (2) | JP7607938B2 (https=) |
| KR (1) | KR20220034115A (https=) |
| CN (2) | CN114651004B (https=) |
| AU (1) | AU2020291942B2 (https=) |
| CA (1) | CA3143034A1 (https=) |
| MX (2) | MX2021015834A (https=) |
| WO (1) | WO2020252418A2 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240141853A (ko) | 2017-08-03 | 2024-09-27 | 신톡스, 인크. | 자가면역 질환의 치료를 위한 사이토카인 접합체 |
| CA3098930A1 (en) | 2018-09-21 | 2020-03-26 | Innovent Biologics (Suzhou) Co., Ltd. | Novel interleukin-2 and use thereof |
| SG11202102930YA (en) | 2018-11-08 | 2021-04-29 | Synthorx Inc | Interleukin 10 conjugates and uses thereof |
| CN111423510B (zh) * | 2019-01-10 | 2024-02-06 | 迈威(上海)生物科技股份有限公司 | 重组抗人pd-1抗体及其应用 |
| EP3923974A4 (en) | 2019-02-06 | 2023-02-08 | Synthorx, Inc. | IL-2 CONJUGATES AND METHODS OF USE THEREOF |
| EP4017540A1 (en) | 2019-08-23 | 2022-06-29 | Synthorx, Inc. | Il-15 conjugates and uses thereof |
| US12234271B2 (en) | 2019-09-10 | 2025-02-25 | Synthorx, Inc. | Il-2 conjugates and methods of use to treat autoimmune diseases |
| WO2022012428A1 (zh) * | 2020-07-14 | 2022-01-20 | 迈威(上海)生物科技股份有限公司 | 抗pd-1抗体及其稳定制剂 |
| WO2022050401A2 (en) * | 2020-09-01 | 2022-03-10 | Takeda Pharmaceutical Company Limited | Interleukin-2 muteins and uses thereof |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| EP4267600A1 (en) * | 2020-12-23 | 2023-11-01 | Merck Sharp & Dohme LLC | Il-2 muteins for treating autoimmune and inflammatory diseases |
| EP4304724A1 (en) * | 2021-03-09 | 2024-01-17 | F. Hoffmann-La Roche AG | Combination therapy of pd-1-targeted il-2 variant immunoconjugate and anti-tyrp1/anti-cd3 bispecific antibodies |
| WO2022189377A1 (en) * | 2021-03-09 | 2022-09-15 | F. Hoffmann-La Roche Ag | Combination therapy of pd-1-targeted il-2 variant immunoconjugates and fap/4-1bb binding molecules |
| WO2022200525A1 (en) | 2021-03-26 | 2022-09-29 | Innate Pharma | Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging |
| JP2024512714A (ja) * | 2021-03-31 | 2024-03-19 | アンウィタ バイオサイエンシス， インク． | 融合タンパク質、医薬組成物、及び治療適用 |
| CN112724263B (zh) * | 2021-04-02 | 2021-08-03 | 上海偌妥生物科技有限公司 | 改造抗cd20单克隆抗体以提高其药物疗效的方法及其应用 |
| BR112023025331A2 (pt) | 2021-06-09 | 2024-02-27 | Innate Pharma | Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| KR20240019786A (ko) | 2021-06-09 | 2024-02-14 | 이나뜨 파르마 에스.에이. | Cd20, nkp46, cd16에 결합하고 il-2에 접합된 다중특이적 항체 |
| EP4376870A4 (en) * | 2021-07-28 | 2025-07-23 | Anwita Biosciences Inc | INTERLEUKIN-2 MUTEINS, FUSION PROTEINS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS |
| CN113831402A (zh) * | 2021-07-30 | 2021-12-24 | 西安龙腾景云生物科技有限公司 | 一种人白细胞介素2变体及其用途 |
| EP4406965A4 (en) * | 2021-09-22 | 2025-12-17 | Fortvita Biologics Singapore Pte Ltd | INTERLEUKIN-2 MUTANT AND FUSION PROTEIN OF WHICH |
| WO2023076927A1 (en) * | 2021-10-27 | 2023-05-04 | Anwita Biosciences, Inc. | Il-2 fusion proteins, pharmaceutical compositions, and therapeutic applications |
| EP4499846A1 (en) | 2022-03-25 | 2025-02-05 | Universität Zürich | Adenoviral mediated targeting of activated immune cells |
| CN114853909A (zh) * | 2022-05-13 | 2022-08-05 | 南京吉盛澳玛生物医药有限公司 | 新型IL-2与INFα和Fc融合蛋白的设计、制备及用途 |
| CN120225547A (zh) * | 2022-11-17 | 2025-06-27 | 南通壹宸生物医药科技有限公司 | Il-2突变体及其应用 |
| KR102893442B1 (ko) * | 2022-12-23 | 2025-12-01 | 가톨릭대학교 산학협력단 | 켈레리트린 클로라이드 또는 그의 약제학적으로 허용가능한 염을 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물 |
| WO2024199458A1 (en) * | 2023-03-29 | 2024-10-03 | Wuxi Biologics (Shanghai) Co., Ltd. | Il-2 variants with improved stability and compositions thereof |
| WO2024251884A1 (en) | 2023-06-09 | 2024-12-12 | Innate Pharma | Nk cell engager proteins comprising anti-cd20 and ant-nkp46 antibody, linked to il-2 in treatment of r/r b-nhl |
| WO2025059162A1 (en) * | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
| US20260083857A1 (en) * | 2024-09-23 | 2026-03-26 | Cephalon Llc | Anti-pd-1 antibody-attenuated il-2 immunoconjugate formulations |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1985000817A1 (en) * | 1983-08-10 | 1985-02-28 | Amgen | Microbial expression of interleukin ii |
| GB9912350D0 (en) * | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
| FI117667B (fi) * | 2001-07-05 | 2007-01-15 | Univ Zuerich | Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä |
| CN1930300A (zh) * | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验系统 |
| US20060234205A1 (en) * | 2004-03-05 | 2006-10-19 | Chiron Corporation | In vitro test system for predicting patient tolerability of therapeutic agents |
| CU23923B1 (es) * | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
| AU2015301936B2 (en) * | 2014-08-11 | 2019-03-07 | Delinia, Inc. | Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases |
| JP7422480B2 (ja) * | 2016-05-04 | 2024-01-26 | アムジエン・インコーポレーテツド | 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質 |
| JP7148539B2 (ja) * | 2017-04-03 | 2022-10-05 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 免疫抱合体 |
| AU2018347521A1 (en) * | 2017-10-12 | 2020-05-07 | Immunowake Inc. | VEGFR-antibody light chain fusion protein |
| KR20250156190A (ko) * | 2018-06-22 | 2025-10-31 | 큐진 인크. | 인터루킨-2 변이체 및 이의 사용 방법 |
-
2020
- 2020-06-13 WO PCT/US2020/037644 patent/WO2020252418A2/en not_active Ceased
- 2020-06-13 CN CN202080057527.1A patent/CN114651004B/zh active Active
- 2020-06-13 CN CN202511005109.9A patent/CN120795117A/zh active Pending
- 2020-06-13 EP EP20823471.6A patent/EP3983433A4/en active Pending
- 2020-06-13 MX MX2021015834A patent/MX2021015834A/es unknown
- 2020-06-13 AU AU2020291942A patent/AU2020291942B2/en active Active
- 2020-06-13 US US17/618,140 patent/US20220235109A1/en active Pending
- 2020-06-13 JP JP2021573421A patent/JP7607938B2/ja active Active
- 2020-06-13 CA CA3143034A patent/CA3143034A1/en active Pending
- 2020-06-13 KR KR1020227001353A patent/KR20220034115A/ko active Pending
-
2021
- 2021-12-15 MX MX2025014988A patent/MX2025014988A/es unknown
-
2024
- 2024-12-11 JP JP2024216112A patent/JP2025063029A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022536345A5 (https=) | ||
| JP7317159B2 (ja) | キメラ抗原受容体及びその使用方法 | |
| JP2022536347A5 (https=) | ||
| Jazayeri et al. | Fc-based cytokines: prospects for engineering superior therapeutics | |
| JP7575100B2 (ja) | 免疫細胞活性化のための二重特異性抗体 | |
| JP2023182757A (ja) | 調整可能な親和性を有する免疫調節タンパク質 | |
| JP2022109915A (ja) | Ｃｄ８０バリアント免疫調節タンパク質およびその使用 | |
| JP2023506452A5 (https=) | ||
| JP2023506454A5 (https=) | ||
| US20130011401A1 (en) | Soluble proteins for use as therapeutics | |
| KR102724621B1 (ko) | 이종이량체화 Ig 도메인 | |
| JP2013531470A5 (https=) | ||
| JP2020511143A5 (https=) | ||
| JP2019533449A (ja) | 多量体ｉｌ−１５に基づく分子 | |
| JP2019510812A (ja) | 多重特異性分子 | |
| WO2014145159A2 (en) | Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use | |
| JP2023138962A (ja) | Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用 | |
| CN106999587A (zh) | 多价中间表位，中间表位结合抗体及其用途 | |
| CA3173414A1 (en) | Pd-1 agonist multimeric binding molecules | |
| TW202334204A (zh) | 條件性活化之抗原結合多肽複合物及其使用方法 | |
| JP2023532278A5 (https=) | ||
| JP2024507693A (ja) | 二重特異性抗体 | |
| US20250188166A1 (en) | Il-18 polypeptides fused to immune cell antigen specific binding polypeptides and uses thereof | |
| KR20230141839A (ko) | 전하쌍을 갖는 이중 특이성 항체 및 이의 용도 | |
| KR20230098334A (ko) | Cldn6 및 cd3에 선택적으로 결합하는 폴리펩디드 작제물 |